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Molecular techniques have become quite crucial for diagnostic histopa-
thology. Their application in sarcomas, both in bone as well as in soft
tissue, have been quite successful. Being sarcomas quite rare and diag-
nostically challenging, the use of ancillary molecular diagnostic tools is
quite useful. Furthermore, thanks to the results of previous and ongoing
research, specific genetic alterations are found to be strongly associated
with several distinct mesenchymal lesions. Molecular techniques allow:
1. better disease definition and therefore more accurate diagnostics,
2. identification of molecular predictive and prognostic markers, 3. unrav-
elling novel molecular targets for more specific therapeutic approach and
eventual drug development. The pathologist has a crucial role: 1. in
selecting the adequate materials for these analyses, 2. choosing the
adequate technology for the given questions and 3. in integrating the
results of these analyses with the clinico-pathological features to render
a final diagnosis. Here we review the major applications of this approach
and discuss its use and limits.
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The integration of molecular techniques has been having
a substantial impact on the pathology practice. In particular the
most relevant changes caused by such approach are: 1. better
disease definition and therefore more accurate diagnostics,
2. identification of molecular predictive and prognostic markers,
3. unravelling novel molecular targets for more specific thera-
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DIAGNOSTIC HISTOPATHOLOGY 18:2 81This review will focus on the applications of the molecular
techniques for soft and bone tumours. Molecular techniques
routinely applied in pathology analyze nucleic acids (RNA and
DNA), either via hybridization on a cut slide (i.e. in situ
hybridization: ISH or fluorescent in situ hybridization: FISH) or
on isolated DNA or RNA via polymerase chain reaction (PCR)
techniques (i.e. reverse transcriptase PCR, quantitative PCR,
etc.). The pathologist has a crucial role in correctly driving such
analyses. In particular: 1 proper material should be selected in
terms of adequate amount of “vital” (non-necrotic) lesional
tissue (>50%), 2 all the results should be interpreted on the light
of the pathology and clinical evidences.Molecular tools for soft tissue and bone tumours diagnostics
Primary soft tissue and bone tumours are a heterogeneous group
of tumours including benign and malignant lesions. They have
a mesenchymal origin, presumably from mesenchymal stem
cells.2 The diagnosis of these lesions may be challenging in daily
pathological practice for several reasons. First of all, as a group,
they are rare (sarcomas, the malignant mesenchymal tumours,
are less than 2% of all cancers) but over 100 subtypes are
described.3 Furthermore morphologic criteria used to recognize
malignancy in other fields are not always applicable.3 In other
words: histologically “ominous” looking lesions may be benign
(i.e. nodular fasciitis or ancient schwannoma) and deceptively
“bland” lesions may have a malignant behaviour (i.e. low grade
fibromyxoid sarcoma or epithelioid sarcoma).3
In this setting the use of ancillary molecular techniques is
diagnostically beneficial. The successful integration of these
techniques relies also on the fact that many of these lesions are
known to harbour specific point mutation, gene amplification
and specific translocations (the most common ones are listed in
Table 1). Their occurrence is routinely assessed for diagnostic
(and prognostic and predictive) purposes via FISH and/or RT-
PCR.
The importance of achieving an accurate diagnosis relies on: 1
distinguishing sarcomas from benign mimickers, 2 identifying
specific sarcoma subtypes which may benefit from specific
therapeutic regimens, 3 the efficacy of clinical trials depends on
the accuracy of diagnosis, it is not possible to identify specific
therapeutic regimens if patients with different tumours are
accrued together and not separately investigated.
For the time being we will not address every single mesen-
chymal lesion, its differential diagnosis and the role molecular
approach may play in this. We will address paradigmatic cases in
which the application of molecular techniques is widely used,
crucial for the diagnosis and ultimately for the treatment. The
principles hereby described may be used also in other circum-
stances, for the remainder cases we refer the reader to more
exhaustive literature.3,4Distinguishing benign from malignant lesionsAs above mentioned, morphological appearance of mesenchymal
lesions is not always reflecting clinical behaviour. This is
particularly true for deceptively bland looking sarcomas.
In particular low grade fibromyxoid sarcoma may often be
misdiagnosed as neurofibroma, perineurioma, cellular myxoma,
nodular fasciitis and desmoid-type fibromatosis (Figure 1a). EMA 2011 Elsevier Ltd. All rights reserved.
A list of the most common mutations in soft tissue and bone tumour. This list is not by far exhaustive as many new ones
were already or are in the process of being reported
Tumour Genetic mutation Gene involved
Alveolar rhabdomyosarcoma t(2;13)(q35;q14)
t(1;13)(p36;q14)
PAX3-FOXO1A
PAX7-FOXO1A
Alveolar soft part sarcoma t(X;17)(p11.2;q25) ASPL-TFE3
Angiomatoid fibrous histiocytoma t(12;16)(q13;p11)
t(12;22)(q13;q12)
t(2;22)(q34;q12)
FUS-ATF1
ATF1-EWSR1
EWSR1-CREB1
Aneurysmal bone cyst t16;17)(q22;p13) CDH11-USP6
Atypical lipomatous tumour/dedifferentiated
liposarcoma
Amplification MDM2
Central/periosteal chondrosarcoma Point mutation IDH1/IDH2
Clear cell sarcoma t(12;22)(q13;q12)
t(2;22)(q34;q12)
ATF1-EWSR1
EWSR1-CREB1
Dermatofibrosarcoma protuberans t(17;22)(q22;q13) COL1A1-PDGFB
Desmoid-type fibromatosis Activating mutation BCTN1
Desmoplastic round cell tumor t(11;22)(p13;q12) WT1-EWSR1
Endometrial stromal sarcoma t(7;17)(p15;q21)
t(6;7)(p21;p15)
t(6;10)(p21;p11)
JAZF1-JJAZ1
PHF1-JAZF1
PHF1-EPC1
Ewing sarcoma/PNET t(11;22)(q24;q12)
t(21;22)(q22;q12)
t(7;22)(p22;q12)
t(17;22)(q12;q12)
t(16;21) (q13;q22)
t(2;22)(q33;q12)
EWSR1-FLI1
EWSR1-ERG
EWSR1-ETV1
EWSR1-EIAF
FUS-ERG
EWSR1-FEV
Extraskeletal myxoid chondrosarcoma t(9;22)(q22;q12)
t(9;15)(q22;q21)
EWSR1eNR4A3
TCF12eNR4A3
TFGeNR4A3
Fibrous dysplasia/intramuscular myxoma Activating mutation GNAS1
Infantile fibrosarcoma t(12; 15)(p13;q25) ETV6-NTRK3
Inflammatory myofibroblastic tumor t(2;19)(p23;p13.1)
t(1;2)(q22-23;p23)
ALK-TPM4
ALK-TPM3
Low grade fibromyxoid sarcoma t(7;16)(q33;p11)
t(11;16)(p11;p11)
FUS-BBF2H7
FUS-CREB3L1
Myxoid/round cell liposarcoma t(12;16)(q13;p11)
t(12;22)(q13;q12)
FUS-DDIT3
EWSR1-DDIT3
Neuroblastoma Amplification N-MYC
Pericytoma with t(7;12) t(7;12)(p22;q13) ACTB-GLI
Pigmented villonodular synovitis t(1;2)(p13;q37) COL6A-CSF1
Soft tissue myoepithelioma t(1;22)(q23;q12)
t(19;22)(q13;q12)
EWSR1-PBX1
EWSR1-ZNF444
Synovial sarcoma t(X;18)(p11;q11) SS18-SSX1
SS18-SSX2
SS18-SSX4
Table 1
MINI-SYMPOSIUM: MOLECULAR DIAGNOSIS IN PATHOLOGYfocal positivity may occur, which makes challenging the differ-
ential diagnosis with perineurioma. In this setting the identifi-
cation of FUS rearrangement via Interphase FISH or the
identification of either FUS-CREB3L1 or FUS-BBF2H7 transcript
via PCR may favour a diagnosis of low grade fibromyxoid
sarcomas (Figure 1b). Recently, data coming from expression
profile of low grade fibromyxoid sarcomas allowed to identifyDIAGNOSTIC HISTOPATHOLOGY 18:2 82a novel marker for its differential diagnosis. MUC4 seem to be
consistently overexpressed in low grade fibromyxoid sarcomas
also at the protein level, which can be assessed by immunohis-
tochemistry5 (Figure 1c). Since low grade fibromyxoid sarcoma is
low grade malignant sarcomas, its diagnosis implies wide margin
resection surgery as the golden standard for avoiding
recurrences. 2011 Elsevier Ltd. All rights reserved.
Figure 1 (a) Low grade myxofibrosarcoma is made up of elongated “bland-looking” spindle cells which may closely simulate perineurioma (HE staining
200 original magnification). (b) Identification of the specific FUS rearrangement and its related transcript as either FUS-CREB3L1 or FUS-BBF2H7 is
helpful for the correct diagnosis [Multiplex PCR showed amplified transcript for FUS-CREB3L1 only in the tested tumour (Cþ16114.2) but neither in the
normal tissue (12533/10) nor in the negative control (NTC: water), beta actin is amplified in both the tumour as well as the normal tissue but not in the
negative control (NTC: water) (courtesy of M. Campo dell’Orto MSc)]. (c) Positive immunostain for MUC4 may be useful in dubious case (200 original
magnification).
MINI-SYMPOSIUM: MOLECULAR DIAGNOSIS IN PATHOLOGYRegarding bone tumours, low grade osteosarcomas either
parosteal osteosarcomas as well as central low grade osteosar-
comas may closely simulate benign lesions such as desmoid-type
fibromatosis and fibrous dysplasia, respectively. Both parosteal
osteosarcoma and central low grade osteosarcoma are charac-
terized by amplification of MDM2 gene which may be either
assessed by FISH or, since such amplification results in an
overexpression of the transcript and ultimately of the relative
protein, by immunohistochemistry for MDM2. Furthermore
sporadic desmoid-fibromatosis is harbouring b-catenin mutation
which may be recognized by PCR and direct sequencing. Fibrous
dysplasia (Figure 2a) is caused by activating mutation in GNAS1
gene (Figure 2c), therefore identifying this mutation is useful for
instance to distinguish fibrous dysplasia of the jaw bones from
ossifying fibroma. However the same mutation has been reported
in low grade central osteosarcomas, although in few cases.
Therefore larger studies are needed to confirm/reject an eventual
role for GNAS1 mutation screening as an ancillary diagnostic tool
for this differential diagnosis. This reminds us to use great
caution in interpreting the results of every molecular test. More
importantly integration of the acquired results with the clinico-
pathological features is mandatory.
It is worthy to mention the same activating mutation in
GNAS1 is found also in 50e60% of intramuscular myxoma, alsoFigure 2 (a) Fibrous dysplasia is made up of irregularly shaped trabeculae of
cation) (b) Cellular intramuscular myxoma is made up of bland spindle cells im
lesions are associated with activating mutation of GNAS1 (courtesy of A.M. C
DIAGNOSTIC HISTOPATHOLOGY 18:2 83in the cellular variant (Figure 2b).6 Since this mutation is not
occurring low grade myxofibrosarcoma, mutation screening may
be used for differential diagnosis.Distinguishing specific sarcoma subtypesIdentifying specific sarcoma subtype is important for adequate
treatment. This is exemplified for instance by the recognition,
among small blue round cell tumours of Ewing Sarcoma, alveolar
rhabdomyosarcoma and poorly differentiated synovial sarcoma.
The demonstration by FISH of EWSR1, SS18 and FOXO1 rear-
rangements in Ewing Sarcoma, poorly differentiated synovial
sarcoma and alveolar rhabdomyosarcoma respectively or, alter-
natively, of specific chimerical transcripts by PCR based tech-
niques, is of great help for achieving a correct diagnosis. The
correct diagnosis is crucial in such cases since the three
mentioned tumours are treated differently.
Although not yet extensively tested for diagnostic purpose,
IDH1 or IDH2 mutations have been identified in periosteal and
central chondrosarcoma.7 These mutations are not present in
chondroblastic osteosarcoma, therefore IDH1/IDH2 mutation
screening might be extremely useful in challenging cases, for
instance small biopsies, to distinguish these different entities.7
Again this distinction is relevant for therapy decision-making
since osteosarcoma benefits from neoadjuvant therapy whilewoven bone embedded in cellular fibrous tissue (200 original magnifi-
mersed in abundant myxoid matrix (200 original magnification) (c) Both
leton-Jansen MSc, PhD).
 2011 Elsevier Ltd. All rights reserved.
Same genetic alteration can occur in distinct tumours
Translocation Tumor type
ETV6-NTRK3/t(12;15) Infantile fibrosarcoma
Acute myeloid leukaemia
Secretory breast carcinoma
ALK gene fusions Inflammatory myofibroblastic tumor
Anaplastic large cell lymphoma
FUS-ERG/t(16;21) Ewing’s sarcoma
Acute myeloid leukaemia
ASPL-TFE3/t(X;17) Alveolar soft part sarcoma
Subset of pediatric renal carcinomas
EWS-ATF1/t(12;22) and
EWS-CREB1/t(2:22)
Clear cell sarcoma
Angiomatoid fibrous histiocytoma
Table 2
MINI-SYMPOSIUM: MOLECULAR DIAGNOSIS IN PATHOLOGYsurgery alone is the treatment of choice for central and periosteal
chondrosarcomas.7
As soon as novel specific drugs are available, the need for
a more accurate diagnosis is expected to increase. This is the case
for instance for ectaneiscin 743/trebectedin, a marine alkaloid
which proved to be efficacious in myxoid liposarcoma. The
identification of the two specific fusion products of CHOP/DDIT3
gene with FUS and more rarely with EWSR1 may be extremely
helpful to recognize myxoid liposarcoma in challenging cases
and to apply the adequate therapeutic regime.
As a result of the widespread use of molecular pathology the
range of clinical presentations of many entities has broadened. In
fact, the combination of morphological criteria and genetics has
allowed for identifying rare disease arising at non-canonical
anatomic locations. As a matter of fact Ewing Sarcoma in the
skin, kidney and dura mater or synovial sarcoma at visceral sites
may be now comfortably recognized and diagnosed.8
Molecular tools for predicting the prognosis and drug response
Despite many efforts to identify prognostic molecular markers,
few have been shown to be reliable and useful in clinical prac-
tice. In particular, initial reports showed correlation between
presence of variant translocations and different prognosis in
Ewing Sarcoma and synovial sarcoma, however large studies did
not confirm it.9e11 Nevertheless, in alveolar rhabdomyosarcoma
a significant correlation between variants translocation and
prognosis can is found. In gastrointestinal stromal tumors
(GIST), KIT/PDGFRAmutation screening has become relevant for
therapy decision-making. In fact distinct KIT and PGDFRA exons
mutations are associated with different clinical behaviour: i.e.
KIT exon 11 mutation is associated with less aggressive disease
while KIT exon 9 mutation is associated with more aggressive
behaviour. Furthermore distinct mutation type reflects different
objective response rates to imatinib (KIT exon 11 e 64e67%,
KIT exon 9 e 34e37%, and wild-type e 23e37%), different
progression-free survival and overall survival. More importantly
mutational analysis in GIST may impact dose selection: the
progression-free survival of GIST patients with KIT exon 9
mutations was shown to be significantly better in patients treated
with 800 mg per day as compared to 400 mg per day.12
Accordingly, the guidelines by European Society of Medical
Oncology (ESMO) have stressed the importance of GIST geno-
typing for its importance in the context of therapeutic planning in
both localized and metastatic GIST.13
Novel drug targets identification
Bases on Success with Imatinib, new kinase inhibitors with
activity against KIT and PDGFRA have been investigated. Among
these Sunitinib (Sutent), an orally bioavailable “multi-targeted”
inhibitor, that also blocks VEGFR2 and may impede tumor angio-
genesis. Sunitinib is FDA-approved for the treatment of GIST
patients who are either intolerant or resistant to Imatinib. Results
from phase II trial showed the best responses to Sunitinib to occur
in patients with KIT exon 9-mutation or wild-type tumor.14
There are many other kinase inhibitors in clinical development,
but one can safely predict that most will eventually fail if used as
a monotherapy. Multi-agent treatment modalities are needed,
perhaps in the formof a kinase inhibitor ‘cocktail’, or a combinationDIAGNOSTIC HISTOPATHOLOGY 18:2 84of a kinase inhibitorwith another targeted therapeutic. Furthermore
impairment of cell cycle/apoptosis regulation may also impair
optimal response to a single tyrosine kinase inhibitor therapy.15
An additional interesting target is MDM2, this is amplified,
among the others, in dedifferentiated liposarcoma, and may be
inhibited by Nutiln-A3.16 Preclinical evidences, mainly generated
by the application of molecular pathology, are needed to design
innovative therapeutic strategies in sarcomas (and in any other
rare form of cancer).
Particularly promising are the results coming from integrated
analyses of DNA sequence, copy number change and mRNA for
identifying a molecular map for possible sarcoma-subtype
specific target.17
Pitfalls in clinical applications of molecular pathology
As we mentioned above molecular pathology/genetics does not
represent an alternative but a complement to surgical diagnostic
pathology. If we consider the degree of molecular promiscuity of
EWSR1 gene aberrations18 as well as the occurrence of the same
genetic aberration in unrelated neoplasms (see Table 2) the result
of molecular analysis has to be integrated with morphology.1
Secondly, it has to be realized that molecular pathology is
characterized by a relatively high methodological complexity. As
a consequence it is necessary that inter-laboratory quality
assessment procedures are implemented.1,19
Thirdly, the availability of frozen material for molecular
testing (as would be required for more sophisticated techniques)
is generally limited.1 A
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